| Eliciting views of Australian pharmaceutical industry employees on collaboration and the concept of Quality Use of Medicines. | |
| | |
MedLine Citation:
|
PMID: 20403068 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Background: Pharmaceutical industry involvement in biomedicine has produced major benefits but has also caused concern. At present, there is no consensus as to how medical and government organizations should relate to the pharmaceutical industry and this is partly due to the absence of systematic study of the various alternatives. In Australia industry cooperation has been elicited through the 'Quality Use of Medicines' (QUM) framework within the 'National Medicines Policy'. Little is known about the way employees of pharmaceutical companies respond to the QUM policy and strategies. Aims: To examine the engagement of the Australian pharmaceutical industry with QUM with a view to assisting medical, government and consumer organizations who may wish to collaborate with industry. Methods: We carried out a qualitative study using in-depth, semistructured interviews with industry employees, primarily from medical and regulatory affairs departments. Results: Employees of pharmaceutical companies claim that collaboration is important, and that they are altruistic and committed to QUM. At the same time, there is little evidence from this study to support the notion that QUM has brought about structural changes to industry or is positioned as the central goal or framework in designing a company's operational strategies. Moreover, there is a significant degree of ambivalence towards governments and medical organizations. Conclusions: Employees within the pharmaceutical industry claim a commitment to collaboration and QUM. While these claims cannot be taken entirely at face value, there is potential for meaningful collaboration with industry. |
| | |
Authors:
|
N Wang; W L Lipworth; J E Ritchie; K M Williams; R O Day |
Related Documents
:
|
11642148 - Common medical terminology comes of age, part two: current code and terminology sets--s... 10289758 - Effective quality controls: the credentialing process and medical staff leadership. 15715828 - Treatment guidelines for depression in the asia pacific region: a review of current dev... 8947988 - Assessing pharmacotherapy outcomes: a model for clinicians. 18317278 - Complementary and alternative medical therapies. 8914298 - Gc/ms comparison of the west indian aphrodisiac "love stone" to the chinese medication ... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Internal medicine journal Volume: 41 ISSN: 1445-5994 ISO Abbreviation: Intern Med J Publication Date: 2011 Apr |
Date Detail:
|
Created Date: 2011-04-21 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101092952 Medline TA: Intern Med J Country: Australia |
Other Details:
|
Languages: eng Pagination: 314-20 Citation Subset: IM |
Copyright Information:
|
© 2011 The Authors. Internal Medicine Journal © 2011 Royal Australasian College of Physicians. |
Affiliation:
|
1 Faculty of Medicine and 2 School of Public Health and Community Medicine, University of New South Wales, 3 Centre for Values, Ethics and the Law in Medicine, Medical Foundation Building (K25), University of Sydney and 4Department of Clinical Pharmacology and Toxicology, St Vincent's Hospital, Sydney, New South Wales, Australia. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Disease-modifying anti-rheumatic drug usage, prescribing patterns and disease activity in rheumatoid...
Next Document: Childhood asthma and GOLD-defined chronic obstructive pulmonary disease.